Clinical Trial

Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer

Study acronym: CISPD-7
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is an single-center, prospective, open-label clinical trial, to explore the safty and efficacy of combination of Bortezomib, Sindilizumab, and mFOLFIRINOX Chemotherapy (oxaliplatin, fluorouracil, irinotecan, leucovorin) in metastatic pancreatic cancer
Protocol Amendment History 1 change
notable Sponsor changed: Zhejiang University -> First Affiliated Hospital of Zhejiang University 2026-08-09
Trial Details
NCT Number NCT06572813
Lead Sponsor Zhejiang University
Conditions Pancreas Cancer
Enrollment 63 participants
Start Date 2024-11-15
Primary Completion 2026-09-01 (estimated)
Study Completion 2028-03 (estimated)
Updated on ClinicalTrials.gov 2025-01-10